| 36.57 -2.75 (-6.99%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 47.22 | 1-year : | 55.15 |
| Resists | First : | 40.43 | Second : | 47.22 |
| Pivot price | 34.93  |
|||
| Supports | First : | 31.96 | Second : | 26.73 |
| MAs | MA(5) : | 38.27 |
MA(20) : | 33.24 |
| MA(100) : | 26.28 |
MA(250) : | 0 | |
| MACD | MACD : | 2.5 |
Signal : | 2 |
| %K %D | K(14,3) : | 86.6 |
D(3) : | 93.3 |
| RSI | RSI(14): 59.1 |
|||
| 52-week | High : | 40.43 | Low : | 12.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MPLT ] has closed below upper band by 37.1%. Bollinger Bands are 116.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 39.32 - 39.53 | 39.53 - 39.71 |
| Low: | 35.14 - 35.39 | 35.39 - 35.6 |
| Close: | 36.28 - 36.66 | 36.66 - 36.99 |
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Fri, 10 Jul 2026
Maplight Therapeutics (NASDAQ:MPLT) Sees Large Volume Increase on Analyst Upgrade - MarketBeat
Fri, 10 Jul 2026
Needham & Company LLC Raises Maplight Therapeutics (NASDAQ:MPLT) Price Target to $45.00 - MarketBeat
Tue, 30 Jun 2026
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout? - Yahoo Finance
Mon, 29 Jun 2026
Number of shareholders of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Thu, 25 Jun 2026
MapLight Therapeutics: The Cobenfy Challenger Does Not Look Like A Bargain (NASDAQ:MPLT) - Seeking Alpha
Wed, 24 Jun 2026
MapLight Therapeutics appoints two directors to board - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 51.1 (%) |
| Held by Institutions | 56 (%) |
| Shares Short | 2,580 (K) |
| Shares Short P.Month | 1,560 (K) |
| EPS | -4.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -49.6 % |
| Return on Equity (ttm) | -81 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -164 (M) |
| Levered Free Cash Flow | -96 (M) |
| PE Ratio | -8.32 |
| PEG Ratio | 0 |
| Price to Book value | 4.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|